OUR MISSION
Viritis was founded in 2023 with a clear goal: to accelerate the development of effective antiviral therapeutics in a world where viral threats evolve faster than traditional drug discovery.
By combining advances in computational biology with programmable PNA-peptide design, we aim to create a new framework for how antiviral medicines are discovered and developed.
A Platform Approach to Antiviral Innovation
We all know the frustration of going to the doctor, only to hear the words “it’s viral, there’s nothing we can do.” Viritis is here to change that reality by developing antiviral treatments that give patients real options, so the world is no longer left unprepared against everyday infections or future viral threats.
Many antiviral programs focus on a single pathogen.
Viritis was built with a different philosophy.
Our research focuses on identifying conserved viral vulnerabilities and developing programmable molecular strategies that can be applied across multiple viral families.
This platform approach enables the development of multiple antiviral assets from a shared technological backbone, creating the potential for a scalable antiviral pipeline.
Why Now
Viritis platform integrates bioinformatics, molecular design, and experimental validation to identify promising therapeutic candidates.
Our multidisciplinary approach combines expertise in:
virology
molecular biology
computational analysis
therapeutic design
This strategy allows us to rapidly translate biological insights into potential therapeutic programs.
Addressing Future Viral Threats
The 2020 viral lockdown highlighted the need for faster and more adaptable antiviral solutions. Future outbreaks will likely involve both known viruses and newly emerging pathogens.
Viritis is focused on building technologies that can respond to this evolving landscape and support the development of antiviral therapeutics across multiple viral targets.
Collaboration and Partnerships
Viritis actively seeks collaborations with pharmaceutical companies, research institutions, and strategic partners interested in advancing antiviral innovation.
We believe that partnerships between academic research, biotechnology, and global pharmaceutical organizations will be essential for bringing next-generation antiviral therapeutics to patients worldwide.
Why Viritis
Platform-based antiviral strategy
Programmable molecular design
Multiple viral programs
Partnership-driven development